Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

1,774

Sector

Medical Equipment, Supplies & Distribution

Calendar

08:00am - San Antonio Breast Cancer Symposium - Abstract Number - PS7-05

More about the company

Quotes

Date	Price	Change	Volume
24-12-10	35.53 $	-2.31%	1,328,916
24-12-09	36.37 $	-1.36%	1,109,014
24-12-06	36.87 $	-0.65%	1,567,821
24-12-05	37.11 $	-2.62%	1,496,005
24-12-04	38.11 $	+6.51%	2,198,051

Delayed Quote Nasdaq, December 10, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart GUARDANT-HEALTH-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36.37USD

Average target price

43.00USD

Spread / Average Target

+18.23%

Consensus

Profit revisions

estimates-change-chart GUARDANT-HEALTH-INC

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GUARDANT-HEALTH-INC

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
35.53 ^USD	-2.31%		+0.03%	+31.35%

Nov. 26	Guardant Health Wins False Advertising Suit Against Natera	MT
Nov. 07	Top Premarket Gainers	MT

Capitalization	4.39B 4.18B 3.87B 3.44B 6.22B 373B 6.89B 48.22B 17.8B 153B 16.48B 16.13B 668B	P/E ratio 2024 *	-10.4x	P/E ratio 2025 *	-11.7x
Enterprise value	4.76B 4.53B 4.2B 3.74B 6.74B 404B 7.47B 52.3B 19.31B 166B 17.88B 17.49B 724B	EV / Sales 2024 *	6.58x	EV / Sales 2025 *	5.87x
Free-Float	-	Yield 2024 *	-	Yield 2025 *	-

Guardant Health Wins False Advertising Suit Against Natera	Nov. 26	MT
Top Premarket Gainers	Nov. 07	MT
Earnings Flash (GH) GUARDANT HEALTH Reports Q3 Revenue $191.5M	Nov. 06	MT
Earnings Flash (GH) GUARDANT HEALTH Reports Q3 Loss $-0.45	Nov. 06	MT
Guardant Health, Inc., Q3 2024 Earnings Call, Nov 06, 2024	Nov. 06
Guardant Health, Inc. Revises Revenue Guidance for the Year 2024	Nov. 06	CI
Guardant Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI
Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director	Oct. 24	CI
Top Premarket Decliners	Sep. 16	MT
Guardant Health, Policlinico Gemelli Collaborate on Liquid Biopsy Testing Service	Sep. 10	MT
Guardant Health, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 11:30 AM	Sep. 05
Top Midday Decliners	Aug. 26	MT
Sector Update: Health Care Stocks Ease in Afternoon Trading	Aug. 26	MT

Nephron Research Downgrades Guardant Health to Sell From Hold, $23 Price Target	Aug. 26	MT
UBS Raises Price Target on Guardant Health to $40 From $32, Maintains Buy Rating	Aug. 21	MT
Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36	Jun. 28	MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	Jun. 04	MT
Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	Jun. 03	MT

Guardant Health, Inc. Stock

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Valuation: Guardant Health, Inc.

Chart: Guardant Health, Inc.

Latest news: Guardant Health, Inc.

Last Transcript: Guardant Health, Inc.

Analysts' recommendations: Guardant Health, Inc.

Press Releases: Guardant Health, Inc.

News in other languages: Guardant Health, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Guardant Health, Inc.

ETFs: Guardant Health, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium	Dec. 09	BU
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal	Nov. 26	AQ
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Nov. 13	BU
Guardant Health: Q3 Earnings Snapshot	Nov. 06	AQ
Guardant Health : Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Form 8 K	Nov. 06	PU

Dans le cadre de l’ESMO 2024, Guardant Health présentera des données démontrant les solides performances de sa technologie d’oncologie de précision dans plusieurs types de tumeurs avancées	Sep. 13
Guardant Health wird auf der ESMO 2024 Daten vorstellen und damit die starke Leistung seiner Präzisionsonkologie-Technologie bei mehreren fortgeschrittenen Tumorarten weiter unter Beweis stellen	Sep. 13
Le test sanguin Shield™ de Guardant Health est approuvé par la FDA en tant qu’option de dépistage primaire, ouvrant la voie au remboursement par Medicare et à une nouvelle ère de dépistage du cancer colorectal	Jul. 29
3 Top-Picks: Auf medizinische KI setzen	Jun. 13
Drie bedrijven om in te zetten op medische AI	Jun. 11

1 day	-2.31%
1 week	+0.03%
Current month	-0.22%
1 month	+24.19%
3 months	+49.47%
6 months	+23.93%
Current year	+31.35%

Director	Title	Age	Since
Michael Wiley DFI	Director of Finance/CFO	48	2012-12-31
AmirAli Talasaz CEO	Chief Executive Officer	44	2021-08-04
Helmy Eltoukhy CEO	Chief Executive Officer	45	2012-12-31

Manager	Title	Age	Since
Helmy Eltoukhy CHM	Chairman	45	2021-08-04
AmirAli Talasaz CHM	Chairman	44	2012-12-31
Ian Clark BRD	Director/Board Member	63	2016-11-30

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	1.22%	0 M€	0.00%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.64%	2 M€	-.--%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GUARDANT HEALTH, INC.	-2.31%	+0.03%	+38.03%	-62.31%	4.49B
BIOMÉRIEUX	-0.20%	+0.51%	+0.12%	-19.67%	12.26B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.29%	-0.51%	-9.44%	+49.07%	7.44B
LANTHEUS HOLDINGS, INC.	-1.73%	+1.56%	+23.43%	+232.17%	6.44B
DIASORIN S.P.A.	+0.24%	-0.86%	+15.19%	-41.60%	5.85B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.07%	-2.46%	-20.95%	-18.56%	3.55B
ANDON HEALTH CO., LTD.	+0.42%	-2.04%	+14.97%	+120.15%	2.7B
VITROLIFE AB	+0.09%	-3.91%	+12.65%	-56.94%	2.69B
10X GENOMICS, INC.	0.00%	-1.94%	-66.93%	-88.75%	1.96B
SANSURE BIOTECH INC.	+0.34%	-1.52%	+21.90%	-37.20%	1.84B
Average	-0.34%	-0.02%	+2.90%	+7.64%	4.92B
Weighted average by Cap.	-0.46%	+0.42%	+5.10%	+19.48%

	2024 *	2025 *
Net sales	724M 689M 639M 568M 1.03B 61.44B 1.14B 7.95B 2.94B 25.23B 2.72B 2.66B 110B	848M 807M 748M 665M 1.2B 71.93B 1.33B 9.31B 3.44B 29.53B 3.18B 3.11B 129B
Net income	-415M -395M -366M -326M -588M -35.26B -652M -4.56B -1.68B -14.48B -1.56B -1.53B -63.18B	-377M -359M -333M -296M -534M -32.02B -592M -4.14B -1.53B -13.15B -1.42B -1.39B -57.38B
Net Debt	372M 354M 328M 292M 526M 31.54B 583M 4.08B 1.51B 12.95B 1.4B 1.37B 56.52B	585M 557M 516M 459M 829M 49.65B 918M 6.43B 2.37B 20.39B 2.2B 2.15B 88.96B